_________
false
C002
÷îäãò áò"î
2
Public
KAMADA LTD
9024
Corporation no:
511524605
Stock Exchange/Market:
-1
1934
380
Sapir 7
P.O.B 4081
,
Ness-Ziona
74036
,
ISRAEL
,
Tel:
08-9406472
,
Fax:
08-9406473
E.mail address:
liatc@kamada.com
Reported via MAGNA:
20/05/2015
Time of broadcast:
08:38
08:35:30
Company site:
www.kamada.com
Reference:
2015-02-023406
Israel Securities Authority
Tel Aviv Stock Exchange
www.isa.gov.il
www.tase.co.il
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Kamada reported updated data from the Company’s European and Canadian Phase 2/3 clinical study of inhaled Alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) during a panel discussion entitled: “New Treatment Prospects for AATD Patients: Results from a Phase 2/3 Inhaled AAT Trial.” The panel, led by Key Opinion Leaders (KOLs) who specialize in treating patients with AATD, was held during the American Thoracic Society (ATS) 2015 International Conference held from May 15-20, 2015 in Denver, Colorado. The slides from the presentation are attached as Exhibit 99.1 and are also available on the Company’s website at www.kamada.com
ATS_2015_ppt__19515_final_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure:
15/04/2015
Name of the Signatory:
:
Cohen Liat
,
Position of Signatory in the reporting corporation:
Company Controller
,
Name of Employer Company:
.
Sapir
Telephone:
08-9913168
,
Facsimile:
08-9912183
,
E-mail:
liatc@kamada.com
1